• 1
    Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoorn MJB et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 2005; 352: 987996.
  • 2
    Perry JR, O′Callaghan CJ, Ding K, Roa W, Mason WP, Cairncross JG et al. A phase III randomized controlled trial of short-course radiotherapy with or without concomitant and adjuvant temozolomide in elderly patients with glioblastoma. J Clin Oncol 2012; 30(Suppl): S2104.
  • 3
    Woehrer A, Zielonke N, Heinzl H, Waldhoer T, Wuertz F, Kiefer A et al. Improved outcome of glioblastoma patients, a population-based study by the Austrian Brain Tumor Registry. Brain Pathol 2010; 20(Suppl 1): 54.
  • 4
    Karsy M, Gelbman M, Shah P, Balumbu O, Moy F, Arslan E. Established and emerging variants of glioblastoma multiforme: review of morphological and molecular features. Folia Neuropathol 2012; 50: 301321.
  • 5
    Dowson N, Rose S, Fay MF, Jeffree RL, Gal Y, Bourgeat P et al. Early prediction of treatment response in advanced gliomas with [18F] FDOPA positron emission tomography. Curr Oncol 2013; (in press).
  • 6
    Mohsen LA, Shi V, Jena R, Gillard JH, Price SJ. Diffusion tensor invasive phenotypes can predict progression-free survival in glioblastomas. Br J Neurosurg 2013; 27: 436441.
  • 7
    Harris RJ, Cloughesy TF, Pope WB, Nghiemphu PL, Lai A, Zaw T et al. 18F-FDOPA and 18F-FLTpositron emission tomography parametric response maps predict response in recurrent malignant gliomas treated with bevacizumab. Neuro Oncol 2012; 14: 10791089.
  • 8
    Pichler BJ, Wehrl HF, Kolb A, Judenhofer MS. Positron emission tomography/magnetic resonance imaging: the next generation of multimodality imaging? Semin Nucl Med 2008; 38: 199208.